World Hungers for Sand while Germany has much of it

This stock photo shows a beach in Monterey, California. (AP)
This stock photo shows a beach in Monterey, California. (AP)
TT

World Hungers for Sand while Germany has much of it

This stock photo shows a beach in Monterey, California. (AP)
This stock photo shows a beach in Monterey, California. (AP)

As incredible as it sounds, the world is running out of sand. Or at least the kind of sand that industries need.

According to the UN Environment Program (UNEP), sand and gravel, known as aggregates, are used in volumes greater than any other raw material on earth except water. And their use greatly exceeds natural renewal rates, the program says.

Kay-Christian Emeis, director of the Institute of Coastal Research at the Helmholtz Center for Materials and Coastal Research (HZG) near Hamburg, Germany, says that worldwide demand for sand is enormous, an estimated 14 billion tons annually, more than half of which is used in Asia.

UNEP explained that sand is indispensable in the industry of many things, such as glass, paper, toothpaste, detergents, cosmetics, electronics and aeronautics, and it is used predominantly in construction and land restorations. Concrete is made with cement, water, sand and gravel.

Even desert countries, like Saudi Arabia and the United Arab Emirates, import sand (marine sand) from Australia, for example to build their skyscrapers.

Harald Elsner, a geologist at Germany's Federal Institute for Geosciences and Natural Resources (BGR) notes that the mineral composition and grain-size distribution of desert sand are not suited to construction.

Most desert sand cannot be used for concrete or land reclamation, as wind erosion shapes round grains that do not blend well, UNEP added.

When Dubai created a group of 300 artificial islands representing a map of the world, it used 450 million tons of Australian sand. As the HZG explains, desert sand would be blown away much too quickly.

The worldwide construction boom, particularly in China, has not left Germany a bystander. According to government statistics, more than 270,000 dwellings in Germany were either newly built or reconstructed in 2016, which is a high record.

This year, the German Construction Industry Federation expects the number to top 300,000.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”